Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine
- PMID: 1409403
- DOI: 10.1023/a:1015860007380
Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine
Abstract
The absorption characteristics of ranitidine after delivery to three locations in the gastrointestinal tract were compared in an open-label study of eight healthy males. Subjects received ranitidine HCl (150 mg) for injection via a nasoenteric tube directly into their stomach, jejunum, or cecum sequentially in three separate periods (24 hr apart). Plasma samples were collected at periodic time intervals for 12 hr following each dosing and analyzed for ranitidine concentration by high-pressure liquid chromatography. Mean concentrations following cecal dosing were lower (P less than 0.05) than concentrations following gastric or jejunal dosing at each sampling time except baseline. Mean concentrations following gastric and jejunal dosing were similar except at 2 hr (gastric greater than jejunal). Mean pharmacokinetic parameters for cecal administration were different (P less than 0.05) from either the gastric or the jejunal periods with the exception of Tmax. There was no difference in any pharmacokinetic parameter after gastric or jejunal dosing. The relative bioavailability after cecal administration was less than 15% of that observed after administration into the stomach or jejunum. Additionally, Wagner-Nelson analysis indicated that the rate of ranitidine absorption was much slower following cecal administration than after gastric or jejunal dosing. Two plasma concentration peaks were observed in three of eight subjects after gastric dosing, in eight of eight subjects after jejunal dosing, and in zero of eight subjects after cecal dosing. These data demonstrate that the absorption profile of ranitidine is equivalent, in extent and duration, after delivery to the stomach or jejunum, while absorption from the cecum is significantly less.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine.Dig Dis Sci. 2000 Aug;45(8):1601-7. doi: 10.1023/a:1005573229786. Dig Dis Sci. 2000. PMID: 11007112 Clinical Trial.
-
Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.Pharm Res. 1996 Oct;13(10):1535-40. doi: 10.1023/a:1016035730754. Pharm Res. 1996. PMID: 8899847
-
Effect of prokinetic agents, cisapride and metoclopramide, on the bioavailability in humans and intestinal permeability in rats of ranitidine, and intestinal charcoal transit in rats.Res Commun Mol Pathol Pharmacol. 2000 Nov-Dec;108(5-6):311-23. Res Commun Mol Pathol Pharmacol. 2000. PMID: 11958284 Clinical Trial.
-
Influence of polyethylene glycol 400 on the gastrointestinal absorption of ranitidine.Pharm Res. 2002 Sep;19(9):1368-74. doi: 10.1023/a:1020315228237. Pharm Res. 2002. PMID: 12403075
-
Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine.J Clin Gastroenterol. 1983;5 Suppl 1:81-90. doi: 10.1097/00004836-198312001-00008. J Clin Gastroenterol. 1983. PMID: 6317740 Review.
Cited by
-
Bias in the Wagner-Nelson estimate of the fraction of drug absorbed.Pharm Res. 2002 Apr;19(4):470-6. doi: 10.1023/a:1015195612726. Pharm Res. 2002. PMID: 12033382
-
Use of the InteliSite capsule to study ranitidine absorption from various sites within the human intestinal tract.Pharm Res. 1998 Dec;15(12):1869-75. doi: 10.1023/a:1011910223812. Pharm Res. 1998. PMID: 9892471 Clinical Trial.
-
Gastrointestinal transit and distribution of ranitidine in the rat.Pharm Res. 1995 Sep;12(9):1316-22. doi: 10.1023/a:1016221606898. Pharm Res. 1995. PMID: 8570528
-
Sumatriptan absorption from different regions of the human gastrointestinal tract.Pharm Res. 1995 Jan;12(1):138-43. doi: 10.1023/a:1016211409315. Pharm Res. 1995. PMID: 7724476
-
Absorption of propranolol in humans following oral, jejunal, and ileal administration.Pharm Res. 1998 Jun;15(6):953-7. doi: 10.1023/a:1011997120293. Pharm Res. 1998. PMID: 9647365 Clinical Trial. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources